1 Min Read
Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars approved for the treatment of bone disease. Obodence, referencing Amgen’s Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, as well as for bone loss associated with prostate cancer […] The post Samsung Bioepis announces launch of two new denosumab biosimilars in Europe appeared first on Pharmafile.
Work & Theory on December 6, 2025
Uncategorized